The VBU continues to crumble


















Given the poor sales performance in the VBU, field head count needs to be reduced by 35% ASAP. Give severance to the less tenured reps and let the old timers sweat it out. Bonus should not be paid out when results are as poor as they have been.
 








Given the poor sales performance in the VBU, field head count needs to be reduced by 35% ASAP. Give severance to the less tenured reps and let the old timers sweat it out. Bonus should not be paid out when results are as poor as they have been.
Speak for yourself. Sales are good in my area. Just because you are performing poorly, doesn’t mean the rest of us should suffer.
 








Given the poor sales performance in the VBU, field head count needs to be reduced by 35% ASAP. Give severance to the less tenured reps and let the old timers sweat it out. Bonus should not be paid out when results are as poor as they have been.
It’ll be cheaper to keep the less tenured reps who are going to adapt to the changing landscape of the job (they need the jobs and the careers). The more tenured are just waiting out retirement. Leadership are making a bigger push for it to mimic a more pharma like pursuit of metrics. It’s sad it’s moving away from account based selling to metric driven busy work. I don’t see it moving back to what it used to be.
 
























































The VBU, by all accounts, is facing significant challenges. Leadership has been lacking, and while expectations in the field remain high, the reality is concerning. The VBU alone cannot turn things around for GSK. The situation feels precarious, and without substantial changes in high-level leadership, the outlook appears bleak. It’s a critical time for GSK. Armageddon!!!

 
















The VBU, by all accounts, is facing significant challenges. Leadership has been lacking, and while expectations in the field remain high, the reality is concerning. The VBU alone cannot turn things around for GSK. The situation feels precarious, and without substantial changes in high-level leadership, the outlook appears bleak. It’s a critical time for GSK. Armageddon!!!

I believe I am making a meaningful impact on patients' lives as a member of the VBU. Through my expertise, I help clients maximize their potential in disease prevention.